MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.29% | 6.03% | 67.77% | 62.22% | 13.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.29% | 6.03% | 67.77% | 62.22% | 13.92% |
| Cost of Revenue | 55.83% | -23.66% | 28.71% | -18.42% | -52.20% |
| Gross Profit | -27.31% | 324.16% | 340.48% | 3,631.40% | 455.73% |
| SG&A Expenses | -14.24% | -28.19% | 64.98% | -55.20% | 13.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 558.23% | -79.88% | -1,803.70% | -476.40% | -141.94% |
| Total Operating Expenses | 16.74% | -26.41% | 41.60% | -37.59% | -28.38% |
| Operating Income | -31.99% | 68.13% | 11.00% | 143.39% | 72.92% |
| Income Before Tax | 37.00% | 11.98% | -17.31% | 42.47% | 46.89% |
| Income Tax Expenses | -- | -- | -- | -4,461.36% | -- |
| Earnings from Continuing Operations | 36.96% | 11.98% | -17.31% | 47.26% | 46.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.96% | 11.98% | -17.31% | 47.26% | 46.92% |
| EBIT | -31.99% | 68.13% | 11.00% | 143.39% | 72.92% |
| EBITDA | -55.40% | 75.25% | 24.83% | 161.47% | 79.37% |
| EPS Basic | 39.51% | 14.55% | 19.51% | 65.00% | 64.78% |
| Normalized Basic EPS | -15.38% | 70.00% | 35.56% | 132.50% | 77.78% |
| EPS Diluted | 39.51% | 14.55% | 19.51% | 65.00% | 64.78% |
| Normalized Diluted EPS | -15.38% | 70.00% | 35.56% | 132.50% | 77.78% |
| Average Basic Shares Outstanding | 3.15% | 4.26% | 45.81% | 49.67% | 50.77% |
| Average Diluted Shares Outstanding | 3.15% | 4.26% | 45.81% | 49.67% | 50.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
